Bright Minds Biosciences Inc. (DRUG) delivered a return of 115.18% over the past year. Since DRUG does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Bright Minds Biosciences Inc. one year ago would be worth $21,518 today, representing a gain of $11,518.

Bright Minds Biosciences Inc. (DRUG) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For DRUG, the total return equals the price-only return.

Yes, Bright Minds Biosciences Inc. (DRUG) outperformed the S&P 500 by 90.19 percentage points over the past year. DRUG delivered a total return of 115.18%, compared to the S&P 500's 24.99%. This 90.19pp alpha means investors in DRUG earned more than a passive S&P 500 index fund.

Bright Minds Biosciences Inc. (DRUG) experienced a maximum drawdown of -38.35% over the past year, declining from its peak on 2026-01-07 to its trough on 2026-06-15. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Bright Minds Biosciences Inc. (DRUG)'s long-term returns with dividends reinvested. Over 10 years, the total return is 124.7% (8.4% CAGR) — $10,000 would have grown to $22,467. Over 20 years: 124.7% total return (4.1% CAGR) — $10,000 → $22,467. Over 30 years: 124.7% total return (2.7% CAGR) — $10,000 → $22,467. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Bright Minds Biosciences Inc.'s best calendar year was 2024 with a total return of 1857.6%. Its worst year was 2022 with a total return of -78.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 1935.7 percentage points.